Skip to search formSkip to main contentSkip to account menu

1 ML Octreotide 0.1 MG/ML Injection

Known as: OCTREOTIDE ACETATE 100 ug in 1 mL SUBCUTANEOUS INJECTION, SOLUTION, OCTREOTIDE ACETATE 100 ug in 1 mL INTRAVENOUS INJECTION, SOLUTION, octreotide acetate 100 ug in 1 mL INTRAVENOUS INJECTION, SOLUTION [Octreotide Acetate] 
National Institutes of Health

Related topics

Related topics

20 relations
Acetic AcidAcromegalyAdenomaDiarrhea

Broader (1)

Antidiarrheals

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
177 Lu-DOTA-Octreotate Therapy for Neuroendocrine Tumors: A Case Report and Review of the Literature
Favorable outcomes of peptide receptor radiotherapy of neuroendocrine tumors (NET) have been reported during the recent years. A… 
2006
2006
Δοσιμετρία κατά τις θεραπευτικές εφαρμογές με octreotide επισημασμένου με In-111
2004
2004
CHILOTORACE NEONATALE IDIOPATICO TRATTATO CON OCTREOTIDE
2001
2001
Comparison of functional imaging and standard CT in evaluation of disease extent in patients with tumours showing neuroendocrine features.
BACKGROUND The diagnostic approach that should be used in disseminated neuroendocrine tumours (NET) remains a significant… 
2001
2001
[Estimation of efficacy of the octreotide LAR administration in the patients with somatotropinoma].
Acromegaly is caused by excessive secretion of growth hormone by a hypophyseal adenoma type of somatotropinoma. IGF-I is formed… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)